Vaccination of BALB/c mice with Leishmania major amastigote-specific cysteine proteinase

Clinical and Experimental Immunology

Volumn 120, Issue 1, 2000, Pages 134-138

  Rafati, Sima ^a   Baba, A Abraham ^a   Bakhshayesh, M ^a   Vafa, M ^a  

^a PASTEUR INSTITUTE OF IRAN   (Iran)

Author keywords

Amastigote specific cysteine proteinase; Leishmania major; Vaccination

Indexed keywords

AMASTIGOTE CYSTEINE PROTEINASE; CYSTEINE PROTEINASE; FREUND ADJUVANT; PROTOZOAL VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY AFFINITY; ANTIGEN PURIFICATION; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVITY; FEMALE; LEISHMANIA MAJOR; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; VACCINATION;

EID: 0034033603     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2000.01160.x     Document Type: Article

References (29)

1. Bates PA. The developmental biology of Leishmania promastigotes. Exp Parasitol 1994; 79:215-8.
2. Chang KP, Chaudhuri G. Molecular determinates of Leishmania virulance. Annu Rev Microbiol 1990; 44:499-529.
3. Berman JD. Human leishmaniasis: Clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin Infect Dis 1997; 24:684-703.
4. Muller I, Pedrazzini T, Farrell JP, Louis JA. T cell responses and immunity to experimental infection with Leishmania major. Annu Rev Immunol 1989; 7:561-78.
5. Fruth U, Solioz N, Louis JA. Leishmania major interferes with antigen presentation by infected macrophages. J Immunol 1993; 150:1857-64.
6. James SL, Nacy C. Effector functions of activated macrophages against parasites. Curr Opin Immunol 1993; 5:518-23.
7. Reiner SL, Locksley RM. The regulation of immunity to Leishmania major. Annu Rev Immunol 1995; 13:151-77.
8. Mosmann TR, Coffman RL. TH1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989; 7:145-73.
9. Reiner SL, Locksley RM. The regulation of immunity to Leishmania major. Annu Rev Immunol 1995; 13:151-77.
10. Xu D, Liew FY. Protection against Leishmania major infection in genetically susceptible BALB/c mice by gp63 delivered orally in attenuated Salmonella typhimurium. Immunology 1995; 85:1-7.
11. McMahon-Pratt D, Rodriguez D, Rodriguez JR, Zhang Y, Esteban M. Recombinant vaccinia viruses expressing GP46/M-2 protect against Leishmania infection. Infect Immun 1993; 61:3351-9.
12. Kelleher M, Bacic A, Handman E. Identification of a macrophage-binding determinant on lipophosphoglycan from Leishmania major promastigotes. Proc Natl Acad Sci USA 1992; 89:6-10.
13. Rafati S, Couty-Jouve S, Alimohammadian MH, Dowlati Y. Evaluation of cellular immune responses to amastigote soluble Leishmania major antigens in recovered cases of cutaneous leishmaniasis. Med J Islamic Rep Iran 1997; 11:33-38.
14. Rafati S, Couty-Jouve S, Alimohammadian MH, Louis JA. Biochemical analysis and immunogenicity of Leishmania major amastigote fractions in cutaneous leishmaniasis. Clin Exp Immunol 1997; 110: 203-11.
15. Glaser TA, Humphris DC, Mukkada AJ. Leishmania major and L. donovani: A method for rapid purification of amastigote. Exp Parasitol 1990; 71:343-5.
16. Scott P, Pearce E, Natovitz P, Sher A. Vaccination against cutaneous leishmaniasis in murine model II. Immunological properties of protective and non protective subfractions of a soluble promastigotes extract. J Immunol 1987; 139:3118-25.
17. Slade SJ, Langhorne J. Production of interferon gamma during infection of mice with Plasmodium chabaudi. Immunobiol 1989; 179:353-65.
18. Mosmann TR, Schumacher JH, Fiorentino DF, Leverah J, Moore KW, Bone MW. Isolation of monoclonal antibodies specific for IL-4, IL-5, IL-6 and a new Th2 specific cytokine, by solid phase radioimmunoadsorbent assay. J Immunol 1990; 145:2938-45.
19. Prat M, Gribaudo G, Comoglio PM, Cavallo G, Landolfo S. Monoclonal antibodies against murine γ interferon. Proc Nat Acad Sci USA 1984; 81:4515-9.
20. Schumacher JH, O'Garra A, Shrader B, Vankimmenade A, Bond MW, Mosmann TR, Coffman RL. The characterization of four monoclonal antibodies specific for mouse IL-5 and development of mouse and human IL-5 enzyme linked immunsorbent. J Immunol 1988; 141: 1576-81.
21. Scott P, Casper P, Sher A. Protection against Leishmania major in BALB/c mice by adoptive transfer of a T cell clone recognizing a low molecular weight antigen released by promastigotes. J Immunol 1990; 144:1075-9.
22. Scott P, Pearce P, Natovitz P, Sher A. Vaccination against cutaneous leishmaniasis in a murine model I. Induction of protective immunity with a soluble extract of promastigotes. J Immunol 1987; 139:221-7.
23. Scott P. IFN-γ modulates the early development of Th1 and Th2 responses in murine model of cutaneous leishmaniasis. J Immunol 1991; 147:3149-55.
24. Gurunathan S, Sacks D, Glaichenhaus N, Seder RS. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major. J Exp Med 1997; 186:1137-47.
25. Webb JR, Campose-Neto A, Reed SG. Human and murine immune responses to novel Leishmania major recombinant protein encoded of a multicopy gene family. Infect Immun 1998; 66:3279-89.
26. Spizer N, Jardim A, Lippert D, Olafson RW. Long-term protection of mice against Leishmania major with a synthetic peptide vaccine. Vaccine 1999; 17:1298-300.
27. Alexander J, Coombs GH, Mottram JC. Leishmania mexicana cysteine proteinase-deficient mutants have attenuated virulence for mice and potentiate a Th1 response. J Immunol 1998; 161:6794-801.
28. Wolfram M, Ilg T, Mottram JC, Overath P. Antigen presentation by Leishmania mexicana-infected macrophages: activation of helper T cells specific for amastigote cysteine proteinases requires intracellular killing of the parasites. Eur J Immunol 1995; 25:1094-100.
29. Soong L, Monroe Duboise S, Kima P, McMahan-Pratt D. Leishmania pifanoi amastigote antigens protect mice against cutaneous leishmaniasis. Infect Immun 1995; 63:3559-66.